Uprosertib

Research use only, not for human use.

Uprosertib (GSK2141795) is a selective, ATP-competitive, and orally bioavailable Akt inhibitor with IC50 of 180 nM, 328 nM, and 38 nM for Akt 1, 2 and 3, respectively. Phase 2.

Uprosertib, also known as GSK2141795 and GSK795, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GSK2141795 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

GSK2141795, GSK 795, Uprosertib

Others

Other Targets

Akt1; Akt2; Akt3

Cancer

——

1047634-65-0

429.25

C18H16Cl2F2N4O2

97%

DMSO : ≥ 150 mg/mL 349.45 mM H2O : < 0.1 mg/mL

Cn1c(c(cn1)Cl)c1c(oc(c1)C(=O)N[C@@H](Cc1cc(c(cc1)F)F)CN)Cl

N-((S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)furan-2-carboxamide

(-20℃)

With Ice Pack

≥ 2 years